MiniPEGylation
Creabilis has developed a proprietary approach to producing drug-like kinase inhibitors called MiniPEGylation. This involves the conjunction of small molecules with very low molecular weight polyethylene glycol (PEG) chains to modify their characteristics in ways which optimises their potential as therapeutic agents.
MiniPEGylation underpins the most advance Creabilis' in-house programme, CT327 for psoriasis and dermatitis.
MiniPEGylation can be used to:- Confer water solubility to even highly hydrophobic drugs
- Produce hydrophilic drugs that can easily cross cell membranes
- Increase the accumulation of drugs in cells by hindering cellular efflux pumps
- Modify the selectivity of pre-existing ATP-competitive kinase inhibitors in a highly defined way
These characteristics enable highly innovative drug discovery and development programs and mark a significant step forward in the use of PEGylation not merely for drug delivery purposes but to provide molecules with new pharmacological properties.
Sede della società: via Ribes 5, 10010 Colleretto Giacosa (TO), Italy - Ufficio del Registro delle Imprese di Torino numero 08661490014 - Capitale sociale versato 1.500.000,00 Euro - Socio Unico: Creabilis SA